Key facts
- Seito Biologics’s last known valuation is $35.8M (Jun 2025).
- It has raised $3.3M; the latest was Early Stage VC ($3.3M) in Jun 2025.
- Notable investors include Lichtsteiner Foundation, University of Zürich.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Seito Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for Seito Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Seito Biologics
Operator of a biotechnology company intended to develop targeted cytokine therapies. The company offers selective Treg cell engagers (TREX) that restore Treg cell function and numbers and corrects the underlying immune dysbalance in autoimmune patients by selectively activating Treg cells without stimulating effector immune cells, and helps to rebalance the immune system, enabling customers to treat immune-mediated disorders, including autoimmune and inflammatory diseases.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Founded
- 2022
- Employees
- 4
- Website
- seitobio.ch/
- Ownership
- Privately Held (backing)
Seito Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Seito Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Seito Biologics in its N-PORT filings yet. We sweep new filings monthly.